Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Connect Twitter with Market Wire News

AGLE Quote Trading Chart Aeglea BioTherapeutics Inc.


home / stock / agle / agle quote

$0.4874 Last:

16.05% Change Percent:

$0.5 Open:

$0.42 Previous Close:

$0.516 High:

$0.4831 Low:

317,085 Volume:

12/31/1969 07:00:00 pm Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

AGLE Last Five Trading Days

Stock DateOpen PriceClose PriceHighLowVolume
2022-08-150.50.420.5160.4831317,085
2022-08-120.48490.420.520.4624445,518
2022-08-110.470.420.5180.45952,955
2022-08-100.420.420.46990.413,197,462
2022-08-090.420.420.450.401287,192
2022-08-080.4410.420.4510.42205,766
2022-08-050.430.420.430.4157282,285
2022-08-040.410.420.420.395276,951
2022-08-030.40290.420.42570.389422,150
2022-08-020.3950.420.39570.372161,238
2022-08-010.410.420.410.39200,924
2022-07-290.41580.420.42950.4171,235
2022-07-280.420.420.430.4056231,326
2022-07-260.43860.43860.44010.4115,819
2022-07-250.43660.40940.43890.409499,656
2022-07-190.46470.47630.48640.4644164,395
2022-07-180.46930.4610.47990.456485,000
2022-07-150.470.46890.48220.46249,754
2022-07-140.480.470.50220.4526252,530
2022-07-130.4830.48210.50760.48533,386
Stock Information

Aeglea BioTherapeutics Inc. Company Name:

AGLE Stock Symbol:

NASDAQ Market:

Aeglea BioTherapeutics Inc. Website:

MENU
AGLE AGLE Quote AGLE Short AGLE News AGLE Articles AGLE Message Board
Get AGLE Alerts

News, Short Squeeze, Breakout and More Instantly...

Ad

KITTEE TRC20 Token Ad
RECENT AGLE NEWS
  • AGLE - Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates

    Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates PR Newswire Cohort 2 Completed in Phase 1/2 Trial of AGLE-177; Data Expected in Fourth Quarter of 2022 Actively Engaged with FDA to Identify Potential Paths Forwar...

  • AGLE - Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

    Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency PR Newswire AUSTIN, Texas , June 2, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnol...

  • AGLE - Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market

    Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market PR Newswire AUSTIN, Texas , May 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company ...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Link Twitter
  • Coins
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Join us on Telegram

Join us on Telegram

Join the Trending Stocks News on Telegram to get immediate news notifications!

Telegram


Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.

WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

Follow @marketwirenews

| Facebook

| Telegram

| LinkedIn

| Reddit

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2022 Market Wire News